By using network pharmacology, we analyzed the differentially expressed genes (DEGs) between patients with NASH and healthy people, screened 293 genes, and finally focused on the core inflammatory cytokine PTGS2 through comparison with the pharmacological targets of POL. Here, PTGS2 is linked to metabolic dysfunction-associated steatohepatitis.